Overview Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis Status: Completed Trial end date: 2008-08-01 Target enrollment: Participant gender: Summary A Multi-center study to determine effects of various doses of Macroflux Parathryroid Hormone (PTH) in women with osteoporosis Phase: Phase 2 Details Lead Sponsor: Zosano Pharma CorporationZosano Pharma Inc.Treatments: Teriparatide